ECONOMIC ANALYSES OF TRASTUZUMAB BIOSIMILAR FOR TREATMENT OF PATIENTS WITH HER2-POSITIVE BREAST CANCER FROM A BRAZILIAN PRIVATE HEALTHCARE PERSPECTIVE

被引：0
|
作者：
Tanaka, S. [1 ]
Suri, G. [2 ]
Despiegel, N. [3 ]
Nascimendo, C. [1 ]
Aratangy, G. [1 ]
机构：
[1] Amgen Inc, Sao Paulo, Brazil
[2] Amgen Inc, London, England
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN147
引用
收藏
页码：S449 / S449
页数：1
相关论文
共 50 条
  • [21] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [22] Trastuzumab Use Modest in Patients With HER2-Positive Breast Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 339 - 339
  • [23] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [24] Duration of trastuzumab for HER2-positive breast cancer
    Montemurro, Filippo
    Aglietta, Massimo
    LANCET ONCOLOGY, 2013, 14 (08): : 678 - 679
  • [25] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
  • [26] Continued trastuzumab therapy for patients with HER2-positive breast cancer
    Haslbauer, F.
    EJC SUPPLEMENTS, 2008, 6 (07): : 221 - 221
  • [27] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Mortimer, Joanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 662 - 663
  • [28] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [29] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [30] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
12345